Crispr Therapeutics initiated with an Outperform at Evercore ISI. Evercore ISI analyst Ravi Mehrotra initiated Crispr Therapeutics with an Outperform rating and a price targets of $46. The analyst says the company’s ex vivo gene therapy gives it a low risk path to market while it continues to refine its delivery systems required for in vivo editing. Mehrotra also cites Crispr’s potential to have several programs in clinic in 2019-2020, along with strong partnerships and clinical execution that “could lead to significant near term clinical news flow.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.